According to recent medical studies, the type 2 diabetes drugs Actos, Byetta and Januvia can greatly increase one's risk of developing bladder or pancreatic cancer. As you can read, the results regarding long term use of diabetes drugs and the increased risks Bladder Cancer and Pancreatic Cancer are alarming.
- Januvia users are 2.7x's more likely to develop pancreatic cancer;
- ACTOS users are 2.0x's more likely to develop bladder cancer;
- Byetta users are 2.9x's more likely to develop pancreatic cancer;
Free & Confidential Diabetes Drug Cancer Lawsuit Help
If you or a loved one has developed pancreatic cancer that you think may be related to taking Actos, Januvia, Janumet, Byetta and Bydureon for diabetes, you may be entitled to financial compensation. Please contact the Willis Law Firm and talk with a Diabetes Drug Cancer lawyer today to discuss your options in a Bladder or Pancreatic Cancer lawsuit. All cases are taken on a Contingency Fee Bases- No Attorney Fees or Expenses Charged to you, unless we win.
Call Toll Free 1-800-883-9858 or CLICK HERE -> FREE CASE REVIEW
Medical Studies Linking Diabetes Drugs and Cancer
Startling information has recently surfaced regarding certain diabetic drugs and cancer. Dr. Peter Butler, a researcher at the University of California, Los Angeles (UCLA), released details of this UCLA Diabetes Study which caused the Food and Drug Administration (FDA) to take a hard look at certain diabetic drugs. The findings of Dr. Butler’s study suggest that there may be a significantly higher risk of pancreatic cancer, pancreatitis, and thyroid cancer when using some diabetic drugs.
Dr. Butler’s research was actually conducted at the behest of Merck, a large manufacturer of some of the diabetic drugs believed to cause cancer. Dr. Butler discovered certain changes in the pancreas of rats that he was studying which might lead to pancreatic cancer.
What Type 2 Diabetes Might Cause Cancer?
Because of Dr. Butler’s thorough research on diabetic drugs and cancer, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have started their own research which may lead to new warnings on diabetic drugs and even potentially to diabetic drug recalls.
The results discovered in Dr. Butler’s diabetic drugs and cancer research were quite startling. He reported that there is as much as a 290% increase in the likelihood of developing pancreatic cancer among those who take one of these diabetic drugs. Further, he claims that there is almost a 500% increase in the likelihood of developing thyroid cancer while taking these same diabetic medications.
The drugs that fall under his research and that are potentially causing cancer include Actos, Januvia, Janumet, Byetta, Bydureon and Victoza.
Actos and Bladder Cancer
Actos is a diabetic drug that has had a tough time staying out of the news for the wrong reasons recently. Prior to the revelation that Actos is a diabetic drug that may cause pancreatic cancer and thyroid cancer, researchers became alarmed at the potential for Actos to cause bladder cancer.
Surprisingly, the potential link between Actos and Bladder cancer was actually acknowledged before Actos was introduced to the market in 1999. Actos’ manufacturer, Takeda Pharmaceuticals, had done the required clinical trials for Actos which actually discovered a high rate of bladder tumors among male rats.
Rather than stopping the production of Actos, the Food and Drug Administration (FDA) allowed Takeda to proceed in selling Actos. Several years after the acceptance of Actos the first human studies of Actos bladder cancer began. In 2007, Takeda acknowledged that there were fairly substantial data suggesting that there may be a link between Actos and bladder cancer.
Not coincidentally, around the same time there were Actos and bladder cancer studies producing startling results elsewhere in the world including France. Both French and German regulators quickly removed Actos from pharmacy shelves and did not allow physicians to continue prescribing the medicine. In the United States, the regulators did not immediately remove Actos from being sold.
Actos Bladder Cancer FDA Study
At this time, there is currently no Actos FDA recall in effect, but people across the country are paying close attention to Takeda pharmaceuticals. After European regulators in Germany and France halted the sale of Actos, the Food and Drug Administration (FDA) required Takeda to begin a 10-year thorough investigation of the potential link between Actos and Bladder Cancer.
Takeda released results at the midpoint of the study in late 2012 and described the situation. After the first 5 years, collecting data from over 100,000 patients taking Actos and a placebo, they determined that individuals taking Actos for more than a year have an increased chance of bladder cancer by 40%. Thus far, these findings have only led to increased clarity on warning labels of the potential risks of Actos and bladder cancer. There has still been no Actos FDA recall.
Byetta, Bydureon and Pancreatic Cancer
Two diabetic drugs that made the list of diabetic drugs that potentially cause cancer are Byetta (generic: exenatide) and Bydureon. Both diabetic drugs are taken via injection and are composed of very similar ingredients. The difference is that Byetta is taken twice daily and Bydureon is only taken once per week. Some patients prefer the convenience of only using one injection per week.
The United States Food and Drug Administration (FDA) has received many complaints since the introduction of Byetta to the market. They have received complaints from patients suffering from pancreatitis, pancreatic cancer, and thyroid cancer among other issues. Byetta was approved by the FDA in mid-2005 and by 2008, they had already received more than 30 FDA Byetta complaints regarding patients suffering from pancreatitis.
There have been at least 2 separate studies which prove that there may be a significant link between the use of Byetta and the incidence of pancreatic cancer and thyroid cancer. The fact that so many patients had reported suffering from pancreatitis is very concerning due to the fact that pancreatitis is one of the leading risk factors for the development of pancreatic cancer.
Januvia, Janumet and Pancreatic Cancer
Two other related drugs making the list of potentially cancer-causing diabetic drugs are Januvia (generic: sitagliptin) and Janumet. Januvia entered the market fairly recently and established a new class of diabetic drugs known as dipeptidyl peptidase-4 (DPP-4). Patients who have been taking Januvia or Janumet may be at an increased risk of suffering from pancreatic cancer or thyroid cancer according to recent medical studies.
The information revealed by Dr. Butler’s studies as well as other research conducted suggested that there may be a significantly greater risk of developing pancreatitis, pancreatic cancer, or thyroid cancer when taking Januvia to treat type-II diabetes.
Since Januvia’s introduction to the American market, the United States Food and Drug Administration (FDA) has received more than 88 complaints of acute pancreatitis, some requiring hospitalization. The danger is that Januvia acute pancreatitis is a leading risk factor of subsequently developing pancreatic cancer. Of those cases, more than half saw the pancreatitis disappear after discontinuing the use of Januvia. This points to a startling potential correlation between Januvia and pancreatic cancer.
Victoza and Pancreatic Cancer
Victoza is the final drug included in our list of the 6 diabetic drugs that have been linked with causing pancreatitis, pancreatic cancer, and thyroid cancer. Victoza is produced by Nordisk, a pharmaceutical manufacturer located in Denmark. Victoza belongs to a class of drugs known as glucagon-like peptide, or GLP-1.
Victoza helps diabetics control their blood sugar levels and promotes insulin production like many other diabetic drugs on the market. According to one patient safety advocacy group, Victoza was approved for use against the advice of three processors in the Food and Drug Administration (FDA). Clinical trials of Victoza suggest that there may be a link between taking Victoza and certain types of cancer and side effects including pancreatitis, pancreatic cancer, and thyroid cancer.
Diabetic Drug and Cancer Lawsuit Help
Each of the drugs mentioned in this article are relatively new to the diabetic drug market, and many doctors and clinicians regret their introduction to the market as they believe that some of the more traditional diabetic drug treatments like metformin may be as effective while limiting the diabetic drug cancer risks.
If you or a loved one has taken Januvia, Janumet, Actos, Byetta, Bydureon, or Victoza and developed pancreatitis, pancreatic cancer, or thyroid cancer, you may be entitled to financial compensation through a Diabetic Drug and Cancer Lawsuit. We are here to offer you help with your diabetic drug lawsuit. Please call us today to speak with a Diabetic drug lawyer regarding your options going forward with a diabetic drug lawsuit. All cases are processed on a contingency fee basis which means that you don’t pay anything unless your case is successful.
Diabetes Drug Cancer Lawsuit
Please contact the Willis Law Firm and talk with a Diabetes Drug Cancer Lawyer today to discuss your options in a Bladder Cancer or Pancreatic Cancer lawsuit. All cases are taken on a Contingency Fee Bases- No Attorney Fees or Expenses Charged to you, unless we win.
Call Toll Free 1-800-883-9858 or CLICK HERE -> FREE CASE REVIEW